Stable Isotope Labeled Zolbetuximab Biosimilar – Anti-CLDN18.2 mAb – Research Grade

Reference: PX-TA1013-SIL-1MG


Product type


Expression system


Product nameStable Isotope Labeled Zolbetuximab Biosimilar - Anti-CLDN18.2 mAb - Research Grade
SourceDrugBank DB15118
Expression systemMammalian cells
Molecular weightLC: 26kDa
BufferPBS pH7.5
Delivery conditionBlue Ice
Delivery Time3-5 days if in stock; 5-8 weeks if production needed
Storage condition4°C for short term; -20°C for long term
Aliases /SynonymsZolbetuximab
Related ProductsPX-P4673
NoteFor research use only. Not suitable for clinical or therapeutic use.
ClonalityMonoclonal Antibody
LabellingArginine: 13C6,15N4 ; Lysine: 13C6,15N2
Isotopic Enrichment99%
Stability1 year

General information about Zolbetuximab

Zolbetiximab is a monoclonal antibody currently under investigation as a potential treatment for pancreatic tumors and gastrointestinal adenocarcinomas. This therapeutic antibody targets isoform 2 of Claudin-18. Claudin-18 protein is encoded by CLDN18 gene and is a member of claudin family of proteins. The members of this family of proteins are key components in the structure of tight junctions also known as zonulae occludentes. Tight junctions form the paracellular space which is the intercellular space between epithelial cells. Claudin family of proteins contain four transmembrane domain whose C-terminus and N-terminus are both located in the cytoplasm. The isoform 2 of CLDN18 protein is restricted to differentiated epithelial cells located at the gastric mucosa tight junctions. However, once malignant transformation occurs, the cell polarity is disturbed and results in isoform 2 CLD18 epitopes being exposed on the surface of cancer cells. Hence, isoform 2 of CLDN18 has been considered as a potential candidate for in targeted therapy for different forms of cancer such as esophagus, pancreatic, ovarian and lung tumors.
Zolbetiximab binds to isoform 2 CLDN18 which results in immune-mediated lysis of this protein. The attachment of Zolbetiximab to isoform 2 CLDN18 causes cancer cell death as a result. Zolbetiximab was in phase II clinical trials as of January 2013. Preliminary results based on phase II ‘FAST’ trial supported zolbetiximab as a potential drug for advanced gastric cancer. Currently zolbetiximab is in phase III of clinical trials. So far zolbetuximab therapy has been well tolerated, Furthermore, the monoclonal antibody showed antitumor activity among patient with isoform 2 CLDN18-positive advanced gastric or gastroesophageal junction cancers. The phase III study consists of administering Zolbetiximab plus mFOLFOX6 vs placebo plus mFOLFOX6. mFOLFOX6 is a combination of three different chemotherapies such as Oxaliplatin, Leucovorin, and Fluorouracil which are also a current treatment option for patients with advanced gastric or gastroesophageal junction adenocarcinoma or cancer. This product is for research use only.


There are no reviews yet.


Be the first to review “Stable Isotope Labeled Zolbetuximab Biosimilar – Anti-CLDN18.2 mAb – Research Grade”

Your email address will not be published. Required fields are marked *

Related products



PX-P4667 221$
Claudin-18 (CLDN18)

Claudin-18 (CLDN18)

PX-P4673 221$
HBV C recombinant protein

HBV C recombinant protein

PX-P5193 414$
Human IgG1 LALA Isotype Control antibody (HyHEL-10)
Isotype Control

Human IgG1 LALA Isotype Control antibody (HyHEL-10)

PTX17885 189$
Zolbetuximab Biosimilar – Anti-CLDN18.2 mAb – Research Grade

Zolbetuximab Biosimilar – Anti-CLDN18.2 mAb – Research Grade

PX-TA1013 476$

Contact us

Send us a message from the form below

    Cart (0 Items)

    Your cart is currently empty.

    View Products